Amgen’s Post

View organization page for Amgen

1,582,814 followers

Предвидимостта – ключът към по-бърз достъп на пациентите до иновации Българските пациенти чакат средно 768 дни, за да получат достъп до нови терапии – с почти 200 дни повече от средното за ЕС (EFPIA W.A.I.T. Indicator 2024). За да преодолеем това изоставане, е нужна предвидима и прозрачна среда, в която институции и фармацевтична индустрия работят в партньорство и споделят обща отговорност към пациентите. 🔹 Само чрез устойчив и последователен диалог можем да гарантираме навременен и равнопоставен достъп до съвременно лечение. 🗣️ „Предвидимостта не означава избягване на отговорност – тя означава споделяне на отговорността по справедлив начин“, каза д-р Алина Кулчеа, Генерален мениджър на Амджен България и Румъния по време на XII Годишна конференция „Иновации и добри практики в здравния сектор“, (11 ноември 2025 г.).

  • No alternative text description for this image
  • No alternative text description for this image

A critical insight into healthcare innovation access in Bulgaria! 🇧🇬 Patients currently face an average wait time of 768 days for new therapies—significantly longer than the European Union average. This underscores the urgent need for a predictable, transparent environment where institutions and the pharmaceutical industry collaboratively share responsibility toward patients. As highlighted by Dr. Alina Kulchea, General Manager of Amgen Bulgaria and Romania, predictability is not about avoiding accountability but about sharing it fairly. Sustained and consistent dialogue is indeed the pathway to ensuring timely and equitable access to modern treatments. Such conversations are vital for advancing healthcare innovation and improving patient outcomes across the region. For More, visit our page: marketaccesstoday.com #Amgen #HealthcareInnovation #HealthcareLeadership #PatientAccess #PharmaceuticalPartnerships #TransparencyInHealth #MarketAccess #MarketAccessToday

Like
Reply

Amgen’s commitment to “building a bridge to broader access” underscores not only innovation but also deep care for patient‑centric medicine.

Like
Reply

Many careers were destroyed in India due to unethical practices by HR and Team Members

Like
Reply
Matthew B.

Clinical Statistician | Clinical Trial Design & Data Analysis | Phase I-III Registered Trials | Director of Clinical Development (Statistical Track)

2d

Тематае болна за много хора. терапии. случва по-бързо and по-честно. Дано разговорите водят и до реални действия.

Like
Reply

I would really love a job if use have please

Like
Reply

One of the worst organisations on the planet, career destroyer organisation in India

Like
Reply
See more comments

To view or add a comment, sign in

Explore content categories